›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Our Companies

Early stage IT and Healthcare Investing

Healthcare

Healthcare

Salmedix

Fri, 06/15/2012 - 09:56 -- anonghost

Salmedix was a start-up biotechnology firm focused on discovering and developing minimally-toxic therapies to treat cancers, particularly those that affect the growing global geriatric population. The company was acquired by Cephalon in May 2005.

NovaCardia

Fri, 06/15/2012 - 09:55 -- anonghost

NovaCardia was a pharmaceutical company focused on developing and commercializing a portfolio of novel small molecule drugs for cardiovascular care. NovaCardia was acquired by Merck in 2007.

Myogen

Fri, 06/15/2012 - 09:54 -- anonghost

Myogen, a University of Colorado Medical Center-based company, developed therapeutics for the treatment of heart disease. The company's strategy was to leverage its molecular and clinical expertise in heart muscle disease to discover new therapeutic targets for drug development, and develop and add value to in-licensed products. Myogen had an initial public offering in 2003, then was acquired by Gilead Pharmaceuticals in 2006.

Inspire Pharmaceuticals

Fri, 06/15/2012 - 09:53 -- anonghost

Inspire Pharmaceuticals discovered and developed breakthrough products to treat diseases involving impaired hydration of the body's mucosal surfaces such as chronic bronchitis and dry eye disease. The products were targeted at disorders with high unmet medical needs representing large, near-term market opportunities. Inspire had an initial public offering in 2000 and was acquired by Merck in 2011.

Dynavax Technologies

Fri, 06/15/2012 - 09:52 -- anonghost

Dynavax Technologies discovers and develops products to prevent and treat infectious and inflammatory diseases. Its clinical-stage product candidates include HEPLISAV ™ Hepatitis B Vaccine, Universal Flu Vaccine , TLR Inhibitor for Lupus and Hepatitis B Therapy. The company partners with AstraZeneca, GlaxoSmithKline and other pharmaceutical companies.

Cubist Pharmaceuticals

Fri, 06/15/2012 - 09:51 -- anonghost

Cubist Pharmaceuticals is focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIND (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. The Cubist product pipeline includes its lipopeptide program and its natural products screening program.

Coulter Pharmaceutical

Fri, 06/15/2012 - 09:50 -- anonghost

Coulter Pharmaceutical developed monoclonal antibody-based anti-cancer drugs that hone in on tumor cells without devastating surrounding healthy tissues. The company's flagship product was the first anti-B1 antibody-based therapy for the treatment of non-Hodgkin's lymphoma. The company merged with Corixa in December 2000, which was subsequently acquired by GlaxoSmithKline.

Corixa

Fri, 06/15/2012 - 09:49 -- anonghost

Corixa was formed in 1994 to develop vaccines and therapeutic products for cancer and infectious diseases based on novel approaches to immunization, stimulation, and culture of cytotoxic T cells and T helper cells. Corixa had an initial public offering in 1997, then was acquired by GlaxoSmithKline in 2005.

COR Therapeutics

Fri, 06/15/2012 - 09:48 -- anonghost

COR was funded to develop and commercialize innovative pharmaceutical products for the treatment and prevention of severe cardiovascular diseases, such as unstable angina, acute ischemic coronary syndrome and stroke. COR went public in 1991 and was acquired by Millennium in 2001.

Cell Genesys

Fri, 06/15/2012 - 09:47 -- anonghost

Cell Genesys is focused on the development and commercialization of biological therapies for patients with cancer. The company is currently pursuing two clinical-stage product platforms — GVAX(R) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include GVAX immunotherapy for prostate cancer, GVAX immunotherapy for pancreatic cancer and leukemia, and a CG0070 oncolytic virus therapy for bladder cancer.

Pages

Subscribe to RSS - Healthcare
Facebook Google+ Twitter Email LinkedIn Share